QL
CRBP icon

Quarry LP’s Corbus Pharmaceuticals CRBP Stock Holding History

Quarry LP’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-750
Closed -$15.5K – 1692
2024
Q3 		$15.5K Buy
750
+350
+88% +$17.9K ﹤0.01% 1177
2024
Q2 		$18.1K Sell
400
-300
-43% -$12.6K 0.01% 1120
2024
Q1 		$27.5K Buy
+700
New +$17.3K 0.01% 769

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quarry LP's CRBP Position: Q4 2024 in Review

Quarry LP sold out of Corbus Pharmaceuticals (CRBP) in Q4 2024, closing a stake of 750 shares — an estimated $15.5K sold.

Quarry LP first reported a position in CRBP in Q1 2024 and held it in 3 quarters. The position peaked at $27.5K in Q1 2024. 99 funds tracked by Wall St. Rank hold CRBP as of Q4 2024.

  • Quarry LP reported no remaining Corbus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Quarry LP sold 750 Corbus Pharmaceuticals shares in Q4 2024, an estimated $15.5K.
  • Quarry LP first reported a position in Corbus Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Quarry LP's Corbus Pharmaceuticals position peaked at $27.5K in Q1 2024.
  • 99 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2024.

Based on Quarry LP's 13F filing for Q4 2024, filed 14 Feb 2025.